Drug Repositioning in Friedreich Ataxia

被引:6
作者
Rufini, Alessandra [1 ,2 ,3 ]
Malisan, Florence [1 ]
Condo, Ivano [1 ]
Testi, Roberto [1 ,2 ]
机构
[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[2] Fratagene Therapeut, Rome, Italy
[3] St Camillus Int Univ Hlth & Med Sci, Rome, Italy
关键词
friedreich ataxia; drug development; frataxin; drug repositioning; therapeutics; RECOMBINANT-HUMAN-ERYTHROPOIETIN; COLONY-STIMULATING FACTOR; INCREASES FRATAXIN PROTEIN; BLOOD-BRAIN-BARRIER; MITOCHONDRIAL BIOGENESIS; DIMETHYL FUMARATE; INTERFERON-GAMMA; MOUSE MODEL; TRANSFERRIN RECEPTOR; CEREBROSPINAL-FLUID;
D O I
10.3389/fnins.2022.814445
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Friedreich ataxia is a rare neurodegenerative disorder caused by insufficient levels of the essential mitochondrial protein frataxin. It is a severely debilitating disease that significantly impacts the quality of life of affected patients and reduces their life expectancy, however, an adequate cure is not yet available for patients. Frataxin function, although not thoroughly elucidated, is associated with assembly of iron-sulfur cluster and iron metabolism, therefore insufficient frataxin levels lead to reduced activity of many mitochondrial enzymes involved in the electron transport chain, impaired mitochondrial metabolism, reduced ATP production and inefficient anti-oxidant response. As a consequence, neurons progressively die and patients progressively lose their ability to coordinate movement and perform daily activities. Therapeutic strategies aim at restoring sufficient frataxin levels or at correcting some of the downstream consequences of frataxin deficiency. However, the classical pathways of drug discovery are challenging, require a significant amount of resources and time to reach the final approval, and present a high failure rate. Drug repositioning represents a viable alternative to boost the identification of a therapy, particularly for rare diseases where resources are often limited. In this review we will describe recent efforts aimed at the identification of a therapy for Friedreich ataxia through drug repositioning, and discuss the limitation of such strategies.
引用
收藏
页数:15
相关论文
共 193 条
[31]   Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia [J].
Chandran, Vijayendran ;
Gao, Kun ;
Swarup, Vivek ;
Versano, Revital ;
Dong, Hongmei ;
Jordan, Maria C. ;
Geschwind, Daniel H. .
ELIFE, 2017, 6
[32]   Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17 [J].
Chang, Ya-Chin ;
Lin, Cheng-Yueh ;
Hsu, Chen-Ming ;
Lin, Hsin-Chieh ;
Chen, Yu-Hsiang ;
Lee-Chen, Guey-Jen ;
Su, Ming-Tsan ;
Ro, Long-Sun ;
Chen, Chiung-Mei ;
Hsieh-Li, Hsiu Mei .
JOURNAL OF NEUROCHEMISTRY, 2011, 118 (02) :288-303
[33]   Src inhibitors modulate frataxin protein levels [J].
Cherubini, Fabio ;
Serio, Dario ;
Guccini, Ilaria ;
Fortuni, Silvia ;
Arcuri, Gaetano ;
Condo, Ivano ;
Rufini, Alessandra ;
Moiz, Shadman ;
Camerini, Serena ;
Crescenzi, Marco ;
Testi, Roberto ;
Malisan, Florence .
HUMAN MOLECULAR GENETICS, 2015, 24 (15) :4296-4305
[34]   Incretins in obesity and diabetes [J].
Chia, Chee W. ;
Egan, Josephine M. .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2020, 1461 (01) :104-126
[35]   Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes [J].
Christensen, M. ;
Sparre-Ulrich, A. H. ;
Hartmann, B. ;
Grevstad, U. ;
Rosenkilde, M. M. ;
Holst, J. J. ;
Vilsboll, T. ;
Knop, F. K. .
INTERNATIONAL JOURNAL OF OBESITY, 2015, 39 (11) :1651-1654
[36]   Epigenetic Promoter Silencing in Friedreich Ataxia is Dependent on Repeat Length [J].
Chutake, Yogesh K. ;
Lam, Christina ;
Costello, Whitney N. ;
Anderson, Michael ;
Bidichandani, Sanjay I. .
ANNALS OF NEUROLOGY, 2014, 76 (04) :522-528
[37]   New developments in pharmacotherapy for Friedreich ataxia [J].
Clay, Alexandra ;
Hearle, Patrick ;
Schadt, Kim ;
Lynch, David R. .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) :1855-1867
[38]   Diabetes in Friedreich Ataxia [J].
Cnop, Miriam ;
Mulder, Hindrik ;
Igoillo-Esteve, Mariana .
JOURNAL OF NEUROCHEMISTRY, 2013, 126 :94-102
[39]   Central Role and Mechanisms of β-Cell Dysfunction and Death in Friedreich Ataxia-Associated Diabetes [J].
Cnop, Miriam ;
Igoillo-Esteve, Mariana ;
Rai, Myriam ;
Begu, Audrey ;
Serroukh, Yasmina ;
Depondt, Chantal ;
Musuaya, Anyishai E. ;
Marhfour, Ihsane ;
Ladriere, Laurence ;
Lopez, Xavier Moles ;
Lefkaditis, Dionysios ;
Moore, Fabrice ;
Brion, Jean-Pierre ;
Cooper, J. Mark ;
Schapira, Anthony H. V. ;
Clark, Anne ;
Koeppen, Arnulf H. ;
Marchetti, Piero ;
Pandolfo, Massimo ;
Eizirik, Decio L. ;
Fery, Francoise .
ANNALS OF NEUROLOGY, 2012, 72 (06) :971-982
[40]   In vivo maturation of human frataxin [J].
Condo, Ivano ;
Ventura, Natascia ;
Malisan, Florence ;
Rufini, Alessandra ;
Tomassini, Barbara ;
Testi, Roberto .
HUMAN MOLECULAR GENETICS, 2007, 16 (13) :1534-1540